← Back to calculator
Limited human topical data; no validated injectable dose
A plain-English reference on GHK-Cu — what it is, its unestablished injectable regulatory status, and the FDA's aggregation, impurity, and immunogenicity safety concerns for compounded copper peptides.
GHK-Cu dosage calculator →
Arithmetic only, not medical advice.
GHK-Cu: reference record
| Regulatory status | No FDA-approved injectable product; FDA reports limited injectable safety data |
|---|---|
| Route | No established injectable treatment route |
| Dosing frequency | No established regimen |
| Published range | No established range |
| Evidence basis | Limited human topical data; no validated injectable dose |
| Common vial sizes | 50, 100 |
Sources
- U.S. Food & Drug Administration - fda.govBasis for the regulatory status, route, frequency and published range in the table above. Source last checked 2026-06-24
What is GHK-Cu?
GHK-Cu is a copper-binding tripeptide, glycyl-L-histidyl-L-lysine complexed with copper. Most of the human evidence behind it concerns topical cosmetic use, which is a fundamentally different exposure from injection.
Is GHK-Cu FDA-approved?
No. There is no FDA-approved injectable GHK-Cu product, and the FDA has reported limited injectable safety data. Cosmetic topical availability is not an approval for injectable use.
How is GHK-Cu given?
There is no established injectable treatment route and no established regimen. No clinically validated injectable dose has been identified.
What are the known safety concerns with GHK-Cu?
Topical and cosmetic evidence must not be extrapolated to injection. The FDA has raised aggregation, impurity and immunogenicity concerns for compounded copper-peptide preparations.
No clinically validated injectable dose identified
No default dose; calculator accepts manual protocol inputs only.
Topical/cosmetic evidence must not be extrapolated to injection; FDA notes aggregation, impurities and immunogenicity concerns.
Supply-chain quality · Finnrick
Avg quality score
7
/10
Purity range
99.6
–
99.97
%
Qty divergence
±
48
%
Vendors · samples
67
·
544
Common vial sizes
50, 100
mg
Test window
Apr 2025 - Jun 2026
Related calculators & comparisons
COMPARISONS
Browse all peptides →